^
    Back
    Association details:
    Biomarker:AR positive
    Cancer:Triple Negative Breast Cancer
    Drug:Erleada (apalutamide) (Androgen receptor antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    Abstract 6271: Hormone receptor inhibition as a strategy for radiosensitization of breast cancer

    Published date:
    05/15/2020
    Excerpt:
    AR inhibition with enzalutamide, apalutamide, and darolutamide showed limited single agent growth inhibition efficacy in AR+ TNBC and AR+, ER+ breast cancer cell lines (IC50 > 10 μM).
    DOI:
    10.1158/1538-7445.AM2020-6271